Article Details
Retrieved on: 2022-10-04 17:34:10
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
By Dean Seal. Pfizer Inc. said the Phase 3 trial studying its drug Talzenna as a treatment for metastatic castration-resistant prostate cancer ...
Article found on: www.marketscreener.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here